Wells Fargo raises Hinge Health stock price target on yield strength
Wells Fargo increased its price target for Hinge Health (HNGE) to $132 from $103, citing strong Q3 results. Revenue was $235M, up 52% YoY, and adjusted EBIT was $77M, both exceeding estimates and guidance. The company also raised its 2026 revenue outlook. HNGE's stock is near its 52-week high, with a 149% YTD return.
How this was made
The 30-second read
Why it matters
The upgrade could trigger further buying, supporting the stock near its 52‑week high.
Market read
Analyst target raise on a fast‑growing health‑tech firm provides a clear short‑term trading catalyst.
What to watch
Potential headwinds from payer reimbursement rates or competition in musculoskeletal therapy.
Background
Wells Fargo's upgrade follows Hinge Health's Q3 earnings beat and FY 2026 guidance raise.
Ticker impact
Wells Fargo raised its price target on Hinge Health to $132 from $103 after the company beat Q3 revenue and EBIT estimates and raised FY guidance.
likely upward pressure as investors price in the higher target and strong earnings beat
The target increase reflects confidence in continued revenue growth and margin expansion, which should attract buying interest.
Market effects
Positive signal for the digital health sector as Hinge Health's strong performance may lift peers.
U.S. market focus; limited regional effect.
Modest, primarily relevant to U.S. investors tracking health‑tech stocks.
Counterpoint
Some investors may view the target raise as already priced in given the recent share rally.
Key entities
- AnalystWells Fargo
Equity research firm that raised the price target.
- CompanyHinge Health Inc
Digital health provider that reported strong Q3 results.
